Noninflammatory adjuvant improving dendritic cell priming and anti-PD-L1 efficacy

被引：0
|
作者：
Seya, Tsukasa [1 ]
Takeda, Yohei [1 ]
Matsumoto, Misako [1 ]
机构：
[1] Hokkaido Univ, Sch Med, Vaccine Immunol, Sapporo, Hokkaido, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
Immunotherapy; Vaccine;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ML10
引用
收藏
页码：551 / 551
页数：1
相关论文
共 50 条
  • [41] Anti-PD-L1 peptide improves survival in sepsis
    Shindo, Yuichiro
    McDonough, Jacquelyn S.
    Chang, Katherine C.
    Ramachandra, Murali
    Sasikumar, Pottayil G.
    Hotchkiss, Richard S.
    JOURNAL OF SURGICAL RESEARCH, 2017, 208 : 33 - 39
  • [42] Suppression of Endometriosis Using Anti-PD-L1 Antibody
    Mamillapalli, Ramanaiah
    Gawde, Nimisha
    Ucar, Abdullah
    Taylor, Hugh S.
    REPRODUCTIVE SCIENCES, 2023, 30 : 198A - 199A
  • [43] Product review: avelumab, an anti-PD-L1 antibody
    Collins, Julie M.
    Gulley, James L.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 891 - 908
  • [44] The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiao-Jiang
    Yuan, Shu-Qiang
    Duan, Jin-Ling
    Chen, Yong-Ming
    Chen, Shi
    Wang, Yun
    Li, Yuan-Fang
    DISEASE MARKERS, 2020, 2020
  • [45] Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy
    Shirasawa, M.
    Yoshida, T.
    Shiraishi, K.
    Takigami, A.
    Takayanagi, D.
    Imabayashi, T.
    Matsumoto, Y.
    Masuda, K.
    Shinno, Y.
    Okuma, Y.
    Goto, Y.
    Horinouchi, H.
    Tsuchida, T.
    Hamamoto, R.
    Yamamoto, N.
    Motoi, N.
    Watanabe, S-I.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1254 - S1254
  • [46] TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy
    Zhu, Xiaoyu
    Yuan, Zile
    Cheng, Sheng
    Wang, Hongyi
    Liao, Yuxuan
    Zhou, Dawei
    Wu, Zhiqiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [47] Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy
    Shirasawa, Masayuki
    Yoshida, Tatsuya
    Shiraishi, Kouya
    Takigami, Ayako
    Takayanagi, Daisuke
    Imabayashi, Tatsuya
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yotsukura, Masaya
    Yoshida, Yukihiro
    Nakagawa, Kazuo
    Tsuchida, Takaaki
    Hamamoto, Ryuji
    Yamamoto, Noboru
    Motoi, Noriko
    Kohno, Takashi
    Watanabe, Shun-ichi
    Ohe, Yuichiro
    LUNG CANCER, 2023, 179
  • [48] TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy
    Xiaoyu Zhu
    Zile Yuan
    Sheng Cheng
    Hongyi Wang
    Yuxuan Liao
    Dawei Zhou
    Zhiqiang Wu
    World Journal of Surgical Oncology, 20
  • [49] EFFICACY AND SAFETY OF ANTI-PD-L1 ANTIBODY IN NSCLC PATIENTS WHO PREVIOUSLY TREATED WITH ANTI PD-1 ANTIBODIES: PRELIMINARY STUDY
    Fujita, Kohei
    Uchida, Naohiro
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Nakatani, Koichi
    Mio, Tadashi
    RESPIROLOGY, 2018, 23 : 167 - 167
  • [50] The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer
    Xu, Fengying
    Zhang, Fengying
    Wang, Qian
    Xu, Ying
    Xu, Shuifang
    Zhang, Caihong
    Wang, Lihua
    BMC IMMUNOLOGY, 2021, 22 (01)
12345